CoChat
Sign Up
Cited by 482Cancer Immunotherapy and BiomarkersLung Cancer Research StudiesLung Cancer Treatments and Mutations

PD-L1 Expression in Lung Cancer

Open access
Yu, Hui, Boyle, Theresa A., Zhou, Caicun, Rimm, David L., Hirsch, Fred R.·2016·Journal of Thoracic Oncology
DOI 10.1016/j.jtho.2016.04.014PMC PMC5353357
Open this paper in CoChat — free accountOpen PDF

Abstract

Immunotherapies targeted against programmed death ligand 1 (PD-L1) and its receptor (PD-1) have improved survival in a subset of patients with advanced lung cancer. PD-L1 protein expression has emerged as a biomarker that predicts which patients are more likely to respond to immunotherapy. The understanding of PD-L1 as a biomarker is complicated by the history of use of different immunohistochemistry platforms with different PD-L1 antibodies, scoring systems, and positivity cut-offs for immunotherapy clinical trials with different anti-PD-L1 and anti-PD-1 drugs. Herein, we summarize the brief history of PD-L1 as a biomarker and describe the challenges remaining to harmonize PD-L1 detection and interpretation for best patient care.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2016.04.014

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Existing predictive biomarkers (PD-L1 expression, TMB, microsatellite instability, and mismatch repair deficiency) have clinical utility in specific contexts, but their predictive accuracy varies considerably across tumor histologies and patient populations.

    “While these markers have clinical utility in specific contexts, their predictive accuracy varies considerably across tumor histologies and patient populations.”

    From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · cites this paper as [10]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 55

  1. [1]Topalian SL Hodi FS Brahmer JR Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 2012 366 2443 2454 22658127 PMC3544539
  2. [2]Brahmer J Reckamp KL Baas P Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med 2015 373 123 135 26028407 PMC4681400
  3. [3]Borghaei H Paz-Ares L Horn L Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer N Engl J Med 2015 373 1627 1639 26412456 PMC5705936
  4. [4]Garon EB Rizvi NA Hui R Pembrolizumab for the treatment of non-small-cell lung cancer N Engl J Med 2015 372 2018 2028 25891174
  5. [6]Freeman GJ Long AJ Iwai Y Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 2000 192 1027 1034 11015443 PMC2193311
  6. [8]Dong H Zhu G Tamada K B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat Med 1999 5 1365 1369 10581077
  7. [9]Hamid O Robert C Daud A Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 2013 369 134 144 23724846 PMC4126516
  8. [10]Brahmer JR Drake CG Wollner I Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates J Clin Oncol 2010 28 3167 3175 20516446 PMC4834717
  9. [11]Thompson RH Kuntz SM Leibovich BC Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up Cancer Res 2006 66 3381 3385 16585157
  10. [12]Motzer RJ Rini BI McDermott DF Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial J Clin Oncol 2015 33 1430 1437 25452452 PMC4806782
  11. [14]Mahoney KM Atkins MB Prognostic and predictive markers for the new immunotherapies Oncology (Williston Park) 2014 28 suppl 3 39 48 25384886
  12. [15]Kim MY Koh J Kim S Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers Lung Cancer 2015 88 24 33 25662388
  13. [16]Schmidt LH Kummel A Gorlich D PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups PLoS One 2015 10 e0136023 26313362 PMC4552388
  14. [17]Tang Y Fang W Zhang Y The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs Oncotarget 2015 6 14209 14219 25895031 PMC4546461
  15. [18]Taube JM Anders RA Young GD Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape Sci Transl Med 2012 4 127ra37 PMC3568523 22461641
  16. [19]Badoual C Hans S Merillon N PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer Cancer Res 2013 73 128 138 23135914
  17. [21]Gettinger SN Horn L Gandhi L Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer J Clin Oncol 2015 33 2004 2012 25897158 PMC4672027
  18. [27]Herbst RS Soria JC Kowanetz M Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 2014 515 563 567 25428504 PMC4836193
  19. [34]Zhang J Gao J Li Y Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics Thorac Cancer 2015 6 534 538 26273411 PMC4511334
  20. [35]Lin C Chen X Li M Programmed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma Clin Lung Cancer 2015 16 e25 e35 25801750
  21. [36]Zhang Y Wang L Li Y Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma Onco Targets Ther 2014 7 567 573 24748806 PMC3990506
  22. [37]Azuma K Ota K Kawahara A Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer Ann Oncol 2014 25 1935 1940 25009014
  23. [38]Yang CY Lin MW Chang YL Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes Eur J Cancer 2014 50 1361 1369 24548766
  24. [39]Velcheti V Schalper KA Carvajal DE Programmed death ligand-1 expression in non-small cell lung cancer Lab Invest 2014 94 107 116 24217091 PMC6125250
  25. [40]Chen YB Mu CY Huang JA Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study Tumori 2012 98 751 755 23389362
  26. [41]Schultheis AM Scheel AH Ozretic L PD-L1 expression in small cell neuroendocrine carcinomas Eur J Cancer 2015 51 421 426 25582496
  27. [42]Ishii H Azuma K Kawahara A Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer J Thorac Oncol 2015 10 426 430 25384063
  28. [43]Komiya T Madan R PD-L1 expression in small cell lung cancer Eur J Cancer 2015 51 1853 1855 26148861
  29. [46]Powles T Eder JP Fine GD MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 2014 515 558 562 25428503
  30. [47]McDermott DF Sosman JA Sznol M Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study J Clin Oncol 2016 34 833 842 26755520
  31. [48]McLaughlin J Han G Schalper KA Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer JAMA Oncol 2015 2 1 9 PMC4941982 26562159
  32. [49]Sharpe AH Wherry EJ Ahmed R The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection Nat Immunol 2007 8 239 245 17304234
  33. [52]Kerr KM Tsao MS Nicholson AG Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol 2015 10 985 989 26134220
  34. [53]Gerdes MJ Sevinsky CJ Sood A Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue Proc Natl Acad Sci U S A 2013 110 11982 11987 23818604 PMC3718135
  35. [56]Taube JM Klein A Brahmer JR Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy Clin Cancer Res 2014 20 5064 5074 24714771 PMC4185001
  36. [57]Akbay EA Koyama S Carretero J Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors Cancer Discov 2013 3 1355 1363 24078774 PMC3864135
  37. [58]Thompson RH Gillett MD Cheville JC Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma Cancer 2005 104 2084 2091 16208700
  38. [59]Thompson RH Gillett MD Cheville JC Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target Proc Natl Acad Sci U S A 2004 101 17174 17179 15569934 PMC534606
  39. [60]Mu CY Huang JA Chen Y High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation Med Oncol 2011 28 682 688 20373055
  40. [61]Phillips T Simmons P Inzunza HD Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer Appl Immunohistochem Mol Morphol 2015 23 541 549 26317305 PMC4561627
  41. [62]Bigelow E Bever KM Xu H Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue [abstract] J Vis Exp 2013 71 4059 PMC3582653 23328703
  42. [63]Soliman H Khalil F Antonia S PD-L1 expression is increased in a subset of basal type breast cancer cells PLoS One 2014 9 e88557 24551119 PMC3925108
  43. [64]Wolff AC Hammond ME Hicks DG Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update [abstract] J Clin Oncol 2013 31 suppl 3997 4013 24101045
  44. [65]Wolff AC Hammond ME Hicks DG Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update Arch Pathol Lab Med 2014 138 241 256 24099077 PMC4086638
  45. [67]Twa DD Chan FC Ben-Neriah S Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma Blood 2014 123 2062 2065 24497532
  46. [71]Rosenberg JE Hoffman-Censits J Powles T Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial [e-pub ahead of print] Lancet http://dx.doi.org/10.1016/S0140-6736(16)00561-4, accessed May 20, 2016. PMC5480242 26952546 · DOI · Paper page
  47. [72]Rudd CE Taylor A Schneider H CD28 and CTLA-4 coreceptor expression and signal transduction Immunol Rev 2009 229 12 26 19426212 PMC4186963
  48. [73]Wing K Onishi Y Prieto-Martin P CTLA-4 control over Foxp3+ regulatory T cell function Science 2008 322 271 275 18845758
  49. [75]Latchman Y Wood CR Chernova T PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nat Immunol 2001 2 261 268 11224527
  50. [76]Youngnak P1 Kozono Y Kozono H Differential binding propeties of B7-H1 and B7-DC to programmed death-1 Biochem Biophys Res Commun 2003 307 672 677 12893276
  51. [77]Yamazaki T Akiba H Iwai H Expression of programmed death 1 ligands by murine T cells and APC J Immunol 2002 169 5538 5545 12421930
  52. [78]Shin SJ Jeon YK Kim PJ Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma: association with oncogenic proteins status Ann Surg Oncol 2016 23 694 702 26464193
  53. [79]Kim S Kim MY Koh J Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas Eur J Cancer 2015 51 2698 2707 26329973
  54. [80]Calles A Liao X Sholl LM Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with KRAS-mutant lung cancer J Thorac Oncol 2015 10 1726 1735 26473645
  55. [81]Champiat S Ileana E Giaccone G Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC J Thorac Oncol 2014 9 144 153 24419410

Cited by

Sorted by citations

Authors
Yu, H., Boyle, T. A., Zhou, C., Rimm, D. L., & Hirsch, F. R.
Affiliations
  • University of Colorado Cancer Center (US)
  • Moffitt Cancer Center (US)
  • Shanghai Pulmonary Hospital (CN)
  • Yale University (US)
Corresponding author
Hirsch, Fred R.
ORCID
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2016-07
Volume
11
Issue
7
Pages
964-975
ISSN
1556-0864 (ISSN-L)
DOI
10.1016/j.jtho.2016.04.014
PMC
PMC5353357
OpenAlex
W2339631364
Cited by
482
References
10
Citations by year
2026: 35 · 2025: 45 · 2024: 72 · 2023: 64 · 2022: 62 · 2021: 77 · 2020: 41 · 2019: 40 · 2018: 24 · 2017: 16 · 2016: 5 · 2015: 1
FWCI
2.85
Type
journal article
Language
en
Update notices
erratum (2017-01-01)
Open access
Licence
Locations
  • Journal of Thoracic Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (5P50CA058187-20)
  • NIH (P50 CA058187)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
PD-L1 expression, lung cancer, PD-1/PD-L1 axis, immunotherapy, predictive biomarkers, immunohistochemistry, PD-L1 inhibitors, scoring system
MeSH terms
Animals, Humans, Immunohistochemistry, Immunotherapy, Lung Neoplasms, Biomarkers, Mice, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review